|Day Low/High||1.34 / 1.36|
|52 Wk Low/High||1.23 / 2.66|
Phase 2a RSV Challenge Study Planned for Q2 2016
Conference Call to be Held Today at 9:00 A.M. EST
Commences Dosing in Phase 1 Multiple Ascending Dose Study with Top-Line Data Expected in 1H 2016
U.S. stock futures are mixed and not moving much as investors gear up for the all-important jobs report Friday morning.
Shareholder rights law firm Johnson & Weaver, LLP continues its investigation into whether certain officers and directors of Biota Pharmaceuticals, Inc, (Nasdaq: BOTA) violated state or federal laws.
Stocks with insider trader activity include CVGW, BOTA and FGP
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CNTY, NCR, RJET, TRT Downgrades: ABEV, BOTA, DTSI, FSLR, L, LE, MWE, VRNT Initiations: CIO, CMFN Read on to get TheStreet Quant Ratings' detailed report:
Phase 2 for Trial for AP611074 in Patients With Anogenital Warts Planned for Late 2015
Stocks with insider trader activity include LLY, BOTA and NWY